Invizyne Technologies (IZTC) Stock Price, News & Analysis

Company Overview

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Key Stats

• Today's Range: $14.90 to $19.78
• 50-Day Range: $10.46 to $20.52
• 52-Week Range: $8.50 to $23.00
• Volume: 79,470 shs
• Average Volume: 40,430 shs
• Market Capitalization: $108.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IZTC Stock Analysis - Frequently Asked Questions

How have IZTC shares performed this year?

Invizyne Technologies' stock was trading at $16.50 on January 1st, 2025. Since then, IZTC stock has increased by 5.5% and is now trading at $17.40.
View the best growth stocks for 2025 here.

When did Invizyne Technologies IPO?

Invizyne Technologies (IZTC) raised $15 million in an initial public offering on Wednesday, November 13th 2024. The company issued 1,875,000 shares at $8.00 per share.

When did Invizyne Technologies' quiet period expire?

Invizyne Technologies' quiet period expired on Monday, December 23rd. Invizyne Technologies had issued 1,875,000 shares in its initial public offering on November 13th. The total size of the offering was $15,000,000 based on an initial share price of $8.00. During Invizyne Technologies' quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Invizyne Technologies?

Shares of IZTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 1/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IZTC
• CUSIP: N/A
• CIK: 2010788
• Web: www.invizyne.com
• Phone: 626-415-1488
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 6,250,000
• Free Float: N/A
• Market Cap: $99.44 million
• Optionable: N/A
• Beta: N/A